. Author manuscript; available in PMC: 2011 Oct 10.

Published in final edited form as: Cardiovasc Toxicol. 2010 Jun;10(2):87–99. doi: 10.1007/s12012-010-9065-z

Table 2.

mtDNA levels in heart tissue from 13- and 26-week-old female CD-1 mice exposed transplacentally to AZT, 3TC, or AZT/3TC^a

Treatment group	Group sizes at 13 weeks (and 26 weeks)^b	Mean mtDNA level ± SE at 13 weeks	Mean mtDNA level ± SE at 26 weeks	Comparisons of values at 13 versus 26 weeks of age (P-value)
Control	n = 7 (10)	37,088 ± 3,720	36,084 ± 3,497	P > 0.05
3TC	n = 4 (4)	32,511 ± 2,167	30,448 ± 4,485	P > 0.05
AZT	n = 8 (8)	67,916 ± 5,477	65,056 ± 4,505	P > 0.05
AZT/3TC	n = 8 (12)	79,465 ± 9,983	74,895 ± 5,768	P > 0.05
Comparisons of NRTI treatment groups versus controls (P-values)		3TC, P > 0.05	3TC, P > 0.05
		AZT, P < 0.001^*	AZT, P < 0.001^*
		AZT/3TC, P < 0.001^*	AZT/3TC, P < 0.001^*
Comparisons of individual NRTI treatment groups (P-values)		3TC vs. AZT, P = 0.003^*	3TC vs. AZT, P = 0.004^*
		3TC vs. AZT/3TC, P < 0.001^*	3TC vs. AZT/3TC, P < 0.001^*
		AZT vs. AZT/3TC, P > 0.05	AZT vs. AZT/3TC, P > 0.05

Values represent the average across all animals measured at specified time points expressed as luminescence units per ng total DNA ± SE; statistical analysis via two-way ANOVA with a Holm-Sidak post hoc test

Twenty-six-week group sizes are given in parentheses

Significant P-values